Dash Bio: $11 Million Closed To Advance Bioanalysis Platform
By Amit Chowdhry ● Jul 23, 2025
Dash Bio, a bioanalysis company specializing in rapid and scalable drug development, has announced an additional $11 million in funding, bringing its total to $17.5 million. Led by The Aligned Fund, investors include Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive Capital, and other notable investors.